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ORIGINAL ARTICLE
FIBTEM clot firmness parameters correlate well with the fibrinogen
concentration measured by the Clauss assay in patients and healthy subjects
Judith J. de Vries , Caroline S. B. Veen, Charlotte J. M. Snoek, Marieke J. H. A. Kruip and
Moniek P. M. de Maat
Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
ABSTRACT
The Clauss assay is the assay most often used for measuring plasma fibrinogen levels. However, the
FIBTEM-assay, determined using thromboelastometry (ROTEM) can also be used to estimate fibrinogen
levels. A major advantage of the FIBTEM is that it can provide information about fibrinogen levels
within minutes, while the Clauss assay needs 30–60min before the result is available. The aim of this
study was to investigate the correlation between fibrinogen levels measured by the Clauss assay and
results from the FIBTEM-assay. We included 111 patients 18 years for whom both ROTEM analyses
and a fibrinogen measurement using the Clauss assay were available. In addition, ROTEM and Clauss
measurements from 75 healthy subjects were included. Spearman correlation was used to determine
the association between the results of both assays. The patients included were mostly patients with
major trauma or undergoing large surgery (e.g. cardiac surgery or liver transplantation). Strong correla-
tions were found between FIBTEM clot firmness parameters and fibrinogen levels measured by the
Clauss assay in patients (Spearman’s correlation coefficients (rs) above 0.80 (p< .001) for all subgroups)
and healthy subjects (rs ¼ 0.66, p< .001). The correlation between early FIBTEM parameters (clot firm-
ness at 5 or 10min) and the maximum clot firmness was almost perfect (rs above 0.96). Also, the cor-
relation between the a-angle and FIBTEM parameters was strong (rs above 0.7). In conclusion, strong
correlations were found between early FIBTEM parameters and fibrinogen levels.
Abbreviations: A5: clot firmness at 5minutes; A10: clot firmness at 10minutes; APTT: activated partial
thrombin time; Crescendo: Clinical Relevance and Significance of New Diagnostic Options in patients
with Unexplained Bleeding; FIBTEM: fibrinogen part of the ROTEM; IQR: interquartile range; MCF: max-
imum clot firmness; PT: prothrombin time; ROC: receiver operating characteristic; ROTEM: rotational
thromboelastometry
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During acute settings accompanied by major blood loss (e.g.
major trauma or complicated surgical procedures), it is
important for clinicians that fibrinogen concentrations are
available as quickly as possible, to guide adequate manage-
ment. The risk of bleeding is increased in individuals when
fibrinogen levels decrease during trauma or surgery and it is
recommended to maintain them above 1.5 g/L [1].
For the most commonly used fibrinogen assay, the Clauss
assay, it takes 30–60min before the result is known in a diag-
nostic laboratory [2]. Another method that is regularly used
in acute settings to rapidly estimate fibrinogen concentration
is rotational thromboelastometry (ROTEM). A specific test of
the ROTEM, the FIBTEM, provides information about the
extrinsic pathway of coagulation, while eliminating the role of
platelets. Therefore, information obtained with this assay
gives an estimate of the contribution of fibrinogen to coagu-
lation. Different parameters can be obtained from the
FIBTEM test, of which the amplitude (or clot firmness) at
5min (A5) or 10min (A10) and the maximum clot firmness
(MCF) are most used for estimating fibrinogen levels.
It is suggested that the A5 can already provide relevant
information about the functional fibrinogen concentration
[3]. In addition, the a-angle might be a good indicator for
the value of the A5 or A10 [4]. Differences in the underly-
ing mechanism of the Clauss assay and FIBTEM test can
give discrepant results, especially in patients with dysfibrino-
genemia or low levels of coagulation factors [5,6]. This is
specifically relevant in trauma patients and patients under-
going large surgeries. Furthermore, in healthy individuals,
heterogeneity in fibrinogen can potentially affect the results
of both assays, resulting in discrepancies [7]. The correlation
between the FIBTEM and Clauss assay has been investigated
before, however only in selected groups of patients [8], and
no information is available for this correlation in healthy
individuals.
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Therefore, the aim of this study was to determine corre-
lations between fibrinogen concentration measured by the
Clauss assay and FIBTEM clot firmness parameters in dif-




Data from all patients aged 18 years for whom both ROTEM
and Clauss assays were ordered as part of routine care in May
or June 2019 in the Erasmus Medical Center Rotterdam were
collected retrospectively for this study. Patients for whom no
results were available for the ROTEM, Clauss assay or APTT
were excluded, there were no other in- or exclusion criteria.
Included patients were divided into the following groups:
major bleeding or other trauma, liver transplantation or other
liver surgery, cardiac surgery (mainly procedures involving
heart valves or aorta) and other (mainly other surgical proce-
dures). The following parameters were obtained from patients
laboratory results: prothrombin time (PT), activated partial
thromboplastin time (APTT), fibrinogen concentration (Clauss
assay) and ROTEM results. Only one measurement of each
patient was included, namely the first measurement in which
the APTT was below 100 s, to exclude results strongly influ-
enced by heparin. Based on the retrospective nature of this
study, this study was not subject to the Medical Research
Involving Human Subjects Act and a waiver for informed con-
sent was granted for the patient group (MEC-2020-0507). As
part of the Crescendo study (Clinical Relevance and
Significance of New Diagnostic Options in patients with
Unexplained Bleeding) healthy individuals were recruited
between July 2016 and March 2018 among employees and stu-
dents of the Erasmus MC University Medical Center [9]. The
Crescendo study was subject to the Medical Research
Involving Human Subjects Act and approved by the Medical
Ethics Committee of the Erasmus University Medical Center
Rotterdam (MEC-2016-218). Written consent was obtained
from each healthy participant. All healthy volunteers with
results of both the ROTEM and Clauss assay (n¼ 75) available
were included in the current study.
Fibrinogen assays
The Clauss assay was performed on a fully automated coagula-
tion analyzer (Sysmex CS-5100 system, Siemens Healthcare
Diagnostics, Breda, the Netherlands). FIBTEM measurements
were performed on the ROTEMVR Delta device, according to
the manufacturer’s instructions (Werfen, Barcelona, Spain).
The following ROTEM parameters were analyzed: clot firm-
ness at 5 or 10min (A5 and A10, respectively), maximum clot
firmness (MCF) and the a-angle.
Statistical analysis
We used descriptive statistics to summarize baseline character-
istics of the study group. Because of a skewed distribution, all
data are presented as median with interquartile range (IQR).
Correlations between the Clauss assay and ROTEM parameters
were tested by non-parametric analyses, determining
Spearman’s correlation coefficients. Kappa statistics was done
to test the agreement in classification in three groups (low,
normal, high) between the two assays. Receiver operating char-
acteristic (ROC) curves were used to determine the best cut-
off value of early FIBTEM parameters to predict low fibrino-
gen levels (below 1.5 g/L). All tests were two-tailed and a p-
value below .05 was considered statistically significant. All stat-
istical analyses were performed using IBM SPSS Statistics 25.
Results
A total of 111 patients of whom both ROTEM and Clauss
assay results were available were included in this study, in
addition to 75 healthy subjects. The median [IQR] age was
60.0 [49.0–69.0] for the patients and 32.0 [26.0–46.0] for the
healthy subjects. 38% of the patients was female, while in
the healthy subjects the fraction of women was 85%. The
majority of patients of whom ROTEM measurements were
available, were patients undergoing cardiac surgery (40%) or
patients that experienced bleedings or other trauma (31%).
Twelve percent of patients had a liver transplantation or
liver surgery and 18% of patients were classified as ‘other’.
In this last group, mainly patients undergoing surgical pro-
cedures, other than cardiac or liver surgery (for example
laparotomy), were included. In the patient subgroups, the
fraction of women was between 16% and 65% (Table 1). As
expected, PT and APTT values were significantly higher in
the patient groups compared to healthy subjects.
The correlation between the clot firmness at 5 or 10min
(A5 and A10) and the maximum clot firmness (MCF) of
the FIBTEM was almost perfect in all patient subgroups and
healthy individuals (rs above 0.96, p< .001) (Figure 1 and
Supplementary Table 1). In addition, the a-angle and the
clot firmness parameters were strongly correlated in all sub-
groups (Table 2).
Figure 2 and Table 2 show the correlations and Spearman’s
correlation coefficients for fibrinogen levels measured by the
Clauss assay and the FIBTEM clot firmness parameters. In
both the patients groups as well as healthy individuals, strong
correlations between the Clauss assay and FIBTEM were
found: rs above 0.80, p< .001 for all patient subgroups and
rs¼0.66, p< .001 for healthy subjects. The correlation in the
healthy individuals is somewhat lower, probably because of the
smaller range of the fibrinogen levels.
In addition, the agreement between the two assays in
classifying fibrinogen levels in low, normal and high was
calculated (Table 3). The fibrinogen measurements were div-
ided in three groups; 1.5 g/L, between 1.5 and 3.5 g/L and
>3.5 g/L. Also the levels of the FIBTEM parameters were
categorized in three groups (lower than or equal to the nor-
mal range, in the normal range, or above the normal range
as provided by the manufacturer of the ROTEM instrument)
(Figure 3). Especially for A10 and MCF, the agreement
between the FIBTEM parameters and the Clauss assay was
found to be strong (K above 0.5, p< .001) (Table 3).
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Finally, we determined the optimal cut-off values of the
FIBTEM parameters to identify fibrinogen levels below
1.5 g/L, based on our study population instead of the general
reference values provided by the manufacturer. This was
only done for the 111 patients, since there were no healthy
subjects with fibrinogen levels below 1.5 g/L. In total, 27 out
Table 1. Study group characteristics.
Characteristic Healthy subjects (n¼ 75) Bleeding/trauma (n¼ 34) Liver surgery (n¼ 13) Cardiac surgery (n¼ 44) Other (n¼ 20)
Age (years) 32.0 [26.0–46.0] 56.0 [33.3–65.0] 52.0 [49.0–66.0] 67.5 [56.3–75.0] 55.0 [42.5–65.5]
Sex (women) 64 (85%) 16 (47%) 6 (46%) 7 (16%) 13 (65%)
PT (s) 11.9 [11.5–12.6] 14.1 [12.3–17.9] 15.1 [12.9–18.0] 15.2 [13.5–16.8] 13.8 [11.7–17.5]
APTT (s) 25.0 [23.0–26.0] 27.5 [24.0–33.3] 30.0 [29.0–33.5] 29.0 [26.0–35.8] 27.0 [23.3–38.3]
Fibrinogena (g/L) 2.7 [2.3–3.4] 1.9 [1.5–2.6] 2.4 [1.9–3.3] 1.9 [1.5–2.2] 3.2 [1.7–4.3]
FIBTEM a–angle 69.0 [64.0–74.0] 69.5 [62.8–75.8] 73.0 [71.0–80.0] 71.0 [67.5–76.5] 74.0 [64.0–77.0]
FIBTEM A5 (mm) ND 11.0 [8.3–13.5] 12.0 [9.0–18.5] 10.5 [7.3–13.0] 14.5 [8.3–19.0]
FIBTEM A10 (mm) 15.0 [12.0–17.0] 11.5 [8.5–14.5] 14.0 [10.0–20.0] 12.0 [9.0–14.0] 15.5 [8.5–22.8]
FIBTEM MCF (mm) 15.0 [12.0–18.0] 12.5 [9.5–16.3] 16.0 [11.0–22.5] 13.0 [9.3–15.0] 17.5 [9.8–24.5]
Data are presented as median [interquartile range] or absolute number (%).
aPatients with major blood loss or very low levels of fibrinogen might have received fibrinogen concentrate, which could have had an impact on these fibrino-
gen measurements.
A5: amplitude (clot firmness) at 5min; A10: amplitude at 10min; APTT: activated partial thromboplastin time; MCF: maximum clot firmness; ND: not determined;
PT: prothrombin time.
Figure 1. Correlation between the maximum clot firmness (MCF) of the FIBTEM assay and early FIBTEM parameters (clot firmness at 5 (A5) or 10 (A10) min).
Table 2. Correlation between fibrinogen level (Clauss assay) or the FIBTEM a–angle and FIBTEM clot firmness parameters.
FIBTEM parameter Healthy (n¼ 75) Bleeding/trauma (n¼ 34) Liver surgery (n¼ 13) Cardiac surgery (n¼ 44) Other (n¼ 20)
A5 vs Clauss 0.846 [0.683–0.918] 0.939 [0.741–0.999] 0.899 [0.805–0.946] 0.808 [0.518–0.943]
A10 vs Clauss 0.697 [0.527–0.829] 0.839 [0.669–0.917] 0.941 [0.755–0.999] 0.899 [0.800–0.946] 0.803 [0.446–0.948]
MCF vs Clauss 0.657 [0.457–0.802] 0.848 [0.678–0.923] 0.935 [0.750–0.991] 0.892 [0.794–0.939] 0.821 [0.496–0.952]
A5 vs a–angle 0.912 [0.788–0.958] 0.917 [0.630–0.998] 0.850 [0.655–0.947] 0.850 [0.568–0.972]
A10 vs a–angle 0.722 [0.575–0.831] 0.900 [0.759–0.952] 0.938 [0.687–1.000] 0.842 [0.634–0.943] 0.837 [0.502–0.978]
MCF vs a–angle 0.718 [0.564–0.829] 0.841 [0.613–0.937] 0.926 [0.700–1.000] 0.777 [0.528–0.900] 0.819 [0.398–0.900]
Data are presented as rs [95% confidence interval]. All p-values <.001.
rs: Spearman’s correlation coefficient; p-values by Spearman’s rank test.
Figure 2. Correlation between fibrinogen concentrations measured by the Clauss assay and maximum clot firmness (MCF) of the FIBTEM assay.
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of 111 patients (24.3%) had fibrinogen levels below 1.5 g/L.
The optimal cut-off value was 9.5 for both A5 and A10
values and 10.5 for MCF (Table 4).
Discussion
We compared the results of fibrinogen levels measured by
the Clauss assay with those of the FIBTEM assay and found
high correlations in different patient groups and healthy
individuals. We also found an almost perfect correlation
between the MCF of the FIBTEM and the A5 or A10, which
implicates that early parameters of the FIBTEM predict the
final clot firmness. Finally, strong correlations were found
between the a-angle and clot firmness parameters, implicat-
ing that faster clot formation also predicts higher
clot firmness.
The correlation between the Clauss assay and the
FIBTEM assay is strong for most patients (rs above 0.80,
p< .001), however some individuals have discrepant values.
This could have been caused by dysfibrinogenemia or low
levels of coagulation factors caused by trauma or surgery.
Previously, other studies have been performed to correlate
FIBTEM measurements with fibrinogen levels measured by
the Clauss assay in different patient groups [8]. In women
with postpartum hemorrhage, moderate to good correlations
have been found between the Clauss assay and FIBTEM
parameters A5, A10 or MCF [10–12]. Also in children [13],
trauma patients [14–16] and patients undergoing liver trans-
plantation [17–19] or cardiac surgery [20,21], moderate to
good correlations have been found between fibrinogen con-
centrations and the different FIBTEM parameters. A poten-
tial confounder in the patients undergoing cardiac surgery
in our study is heparinization, which might have interfered
Table 3. Agreement between the Clauss assay and FIBTEM parameters in classification in low, normal or high fibrinogen.
FIBTEM parameter
(normal range) Healthy subjects (n¼ 75) Bleeding/trauma (n¼ 34) Liver surgery (n¼ 13) Cardiac surgery (n¼ 44) Other (n¼ 20)
A5 (4–17mm) 0.693 [0.452–0.934] 0.350 [–0.107–0.807] 0.138 [–0.066–0.342] 0.381 [0.063–0.699]
A10 (7–23mm) 0.388 [0.711–0.065] 0.885 [0.730–1.040] 1.000 [1.000–1.000] 0.507 [0.256–0.758] 0.514 [0.204–0.824]
MCF (9–25mm) 0.085 [–0.140–0.310] 0.822 [0.634–1.010] 0.851 [0.571–1.131] 0.536 [0.287–0.785] 0.528 [0.218–0.838]
Data are presented as kappa statistics with [95% confidence interval] of the agreement in classification in 3 groups according to fibrinogen level measured by
the Clauss assay (low: 1.5; normal: 1.5–3.5 or high: >3.5 g/L) and FIBTEM parameters (low: below normal range, normal: within normal range, high: above nor-
mal range).
Figure 3. Agreement between classification in low, normal and high levels according to the Clauss assay and FIBTEM parameters clot firmness at 5 (A5) or 10
(A10) min or maximum clot firmness (MCF).
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with the FIBTEM measurements. However, a heparin inhibi-
tor is present in the FIBTEM measurement, neutralizing
high heparin concentrations up to 1U/ml. To exclude sam-
ples with heparin concentrations above 1U/ml, all measure-
ments for which APTT results were above 100 s were not
included in the analyses. In addition, we do not observe a
weaker correlation in patients undergoing cardiac surgery
compared to the other subgroups, suggesting heparin did
not influence the results. A strength of our study was that
we retrospectively compared the results of both assays meas-
ured during normal clinical settings instead of selecting
patients. This shows that the results are applicable to a wide
range of patients. In addition, we included a large healthy
population to compare the Clauss assay with FIBTEM
parameters, which, to our knowledge, has not been reported
before. The correlation between fibrinogen levels and
FIBTEM parameters was slightly lower in healthy individu-
als compared to the patients. This is most likely caused by
the much smaller range of fibrinogen levels in the healthy
individuals.
When both assays were used to classify patients in low,
normal or high levels of fibrinogen in this study, especially
strong agreement was found in patients with bleedings or
other trauma and patients undergoing liver transplantation
or surgery. For patients undergoing cardiac surgery or other
surgeries, the agreement was somewhat lower, which could
have been due to the low number of patients in these
groups. In addition, the reference values based on the
manufacturer of the ROTEM instrument might not have
been the best cut-off values to classify patients in low, nor-
mal or high fibrinogen levels, since the normal values
potentially differ between different laboratories. Therefore,
we determined the optimal cut-off values of the FIBTEM
parameters, based on our study group, to predict whether
fibrinogen levels are below 1.5 g/L. Multiple studies have
looked at optimal threshold values of the early FIBTEM
parameters A5 and A10 to quickly determine if fibrinogen
levels are below a critical point. One study found a similar
threshold for A5 as we did (9.5mm) to determine fibrino-
gen levels below 1.5 g/L in trauma patients [15], while other
studies determined lower threshold levels (5, 6 or 7mm)
[12,20,22,23]. For A10, only one study in patients under-
going cardiac surgery determined the optimal cut-off value,
which was similar to ours [24]. It is important to work with
the optimal cut-off values, because this prevents unnecessary
supplementation of fibrinogen, while the risk of bleeding is
reduced to a minimum.
In the Erasmus Medical Center, according to the massive
blood loss protocol, fibrinogen concentrate is given to
patients when A10 values are 9mm. If A10 values are
7mm or 5mm, increased amounts of fibrinogen concen-
trate are given. The values currently used to guide transfu-
sion of fibrinogen concentrate correspond well to the
optimal cut-off value found in this study: 9.5 for fibrinogen
levels below 1.5. As described above, the reported optimal
cut-off values for FIBTEM parameters to determine low
fibrinogen levels are quite variable across different studies.
This might partially be caused by variation in assays and
reagents per laboratory, and also the type of ROTEM used
contributes to the variation [11]. It is therefore of great
importance for each laboratory to work with reference val-
ues specific for the device used .
A limitation of our study is the retrospective nature,
which may have introduced bias and increases the risk of
statistical errors. However, a selection bias was minimized
by including all patients for which ROTEM and Clauss
measurements were ordered in May and June 2019.
Therefore, this is a good representation of patient popula-
tion for which ROTEM measurements are needed and these
results are relevant. In addition, results from these measure-
ments are not very likely to be wrongly recalled, since the
raw data of these tests are available in the patient laboratory
results. Another limitation is the limited number of subject
with very low or very high fibrinogen levels. However, it is
important to realize that this study was performed in a real-
life hospital setting, there was no selection of samples based
on the fibrinogen level. In addition, the healthy individuals
were more often female and on average much younger than
the patients included in this study, which makes the groups
less comparable to each other. However, the aim of this
research was not to compare these groups, but to investigate
the correlation between the two assays in both groups.
Finally, fibrinogen concentrate might have been given to
patients included in this study, especially after major blood
loss or during large surgeries. We believe this does not have
consequences for our results, since this will both affect the
Clauss assay and ROTEM measurement.
In conclusion, early FIBTEM clot firmness parameters
correlate well with final clot firmness as measured by the
FIBTEM assay and to fibrinogen concentration as measured
by the Clauss assay. This means that early FIBTEM parame-
ters as well as the MCF might be used to evaluate fibrinogen
concentrations, thus saving time in emergency situations.
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Table 4. Optimal cut-off values of FIBTEM parameters for fibrinogen levels
1.5 g/L.
FIBTEM parameter Cut-off value Sensitivity Specificity
A5 9.5 96.3% 82.1%
A10 9.5 85.2% 90.5%
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604 J. J. DE VRIES ET AL.
ORCID
Judith J. de Vries http://orcid.org/0000-0002-5007-2147
References
[1] Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic
target for bleeding: a review of critical levels and replacement
therapy. Transfusion. 2014;54(5):1389–1405.
[2] Whiting M. Impact, meaning and need for help and support:
the experience of parents caring for children with disabilities,
life-limiting/life-threatening illness or technology dependence. J
Child Health Care. 2013;17(1):92–108.
[3] Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic
haemostatic assays in the management of major bleeding: a
British Society for Haematology Guideline. Br J Haematol.
2018;182(6):789–806.
[4] Toffaletti JG, Buckner KA. Use of earlier-reported rotational
thromboelastometry parameters to evaluate clotting status,
fibrinogen, and platelet activities in postpartum hemorrhage
compared to surgery and intensive care patients. Anesth Analg.
2019;128:414–423.
[5] Casini A, Neerman-Arbez M, Ariens RA, et al.
Dysfibrinogenemia: from molecular anomalies to clinical mani-
festations and management. J Thromb Haemost. 2015;13(6):
909–919.
[6] Theusinger OM, Schroder CM, Eismon J, et al. The influence
of laboratory coagulation tests and clotting factor levels on
Rotation Thromboelastometry (ROTEM(R)) during major sur-
gery with hemorrhage. Anesth Analg. 2013;117(2):314–321.
[7] Nieuwenhuizen W. Biochemistry and measurement of fibrino-
gen. Eur Heart J. 1995;16 Suppl A (Suppl A):6–10.
[8] Ranucci M, Dedda DU, BaryshnikovaE. Trials and tribulations
of viscoelastic-based determination of fibrinogen concentration.
Anesth Analg. 2020;130:644–653.
[9] Veen CSB, Huisman EJ, Cnossen MH, et al. Evaluation of
thromboelastometry, thrombin generation and plasma clot lysis
time in patients with bleeding of unknown cause: a prospective
cohort study. Haemophilia. 2020;26(3):e106–e115.
[10] de Lange NM, van Rheenen-Flach LE, Lance MD, et al. Peri-
partum reference ranges for ROTEM(R) thromboelastometry.
Br J Anaesth. 2014;112(5):852–859.
[11] Gillissen A, van den Akker T, Caram-Deelder C, et al.
Comparison of thromboelastometry by ROTEMVR Delta and
ROTEMVR Sigma in women with postpartum haemorrhage.
Scand J Clin Lab Invest. 2019;79(1-2):32–38.
[12] Huissoud C, Carrabin N, Audibert F, et al. Bedside assessment
of fibrinogen level in postpartum haemorrhage by thrombelas-
tometry. BJOG. 2009;116(8):1097–1102.
[13] Haas T, Spielmann N, Mauch J, et al. Comparison of throm-
boelastometry (ROTEM(R)) with standard plasmatic coagula-
tion testing in paediatric surgery. Br J Anaesth. 2012;108(1):
36–41.
[14] Meyer AS, Meyer MA, Sorensen AM, et al.
Thrombelastography and rotational thromboelastometry early
amplitudes in 182 trauma patients with clinical suspicion of
severe injury. J Trauma Acute Care Surg. 2014;76:682–690.
[15] Rourke C, Curry N, Khan S, et al. Fibrinogen levels during
trauma hemorrhage, response to replacement therapy, and
association with patient outcomes. J Thromb Haemost. 2012;
10(7):1342–1351.
[16] Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagula-
tion abnormalities in trauma patients by rotation thrombelas-
tography. J Thromb Haemost. 2007;5(2):289–295.
[17] Hashir A, Singh SA, Krishnan G, et al. Correlation of early
ROTEM parameters with conventional coagulation tests in
patients with chronic liver disease undergoing liver transplant.
Indian J Anaesth. 2019;63(1):21–25.
[18] Song JG, Jeong SM, Jun IG, et al. Five-minute parameter of
thromboelastometry is sufficient to detect thrombocytopenia
and hypofibrinogenaemia in patients undergoing liver trans-
plantation. Br J Anaesth. 2014;112(2):290–297.
[19] Jeong SM, Song JG, Seo H, et al. Quantification of both platelet
count and fibrinogen concentration using maximal clot firm-
ness of thromboelastometry during liver transplantation.
Transplant Proc. 2015;47(6):1890–1895.
[20] Matzelle SA, Weightman WM, Gibbs NM. An audit of the
diagnostic accuracy of rotational thromboelastometry for the
identification of hypofibrinogenaemia and thrombocytopenia
during cardiopulmonary bypass. Anaesth Intensive Care. 2018;
46(6):620–626.
[21] Olde Engberink RH, Kuiper GJ, Wetzels RJ, et al. Rapid and
correct prediction of thrombocytopenia and hypofibrinogene-
mia with rotational thromboelastometry in cardiac surgery. J
Cardiothorac Vasc Anesth. 2014;28(2):210–216.
[22] David JS, Durand M, Levrat A, et al. Correlation between
laboratory coagulation testing and thromboelastometry is modi-
fied during management of trauma patients. J Trauma Acute
Care Surg. 2016;81(2):319–327.
[23] Bouzat P, Guerin R, Boussat B, et al. Diagnostic performance
of thromboelastometry in trauma-induced coagulopathy: a
comparison between two level I trauma centres using two dif-
ferent devices. Eur J Trauma Emerg Surg. 2019.
[24] Mace H, Lightfoot N, McCluskey S, et al. Validity of thromboe-
lastometry for rapid assessment of fibrinogen levels in hepari-
nized samples during cardiac surgery: a retrospective, single-
center, observational study. J Cardiothorac Vasc Anesth. 2016;
30(1):90–95.
SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 605
